Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS

Hongyan Lu, Todd Cook, Christophe Poirier, Stephanie Merfeld-Clauss, Irina Petrache, Keith L. March, Natalia Bogatcheva

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Transplantation of mesenchymal stromal cells (MSCs) has been shown to effectively prevent lung injury in several preclinical models of acute respiratory distress syndrome (ARDS). Since MSC therapy is tested in clinical trials for ARDS, there is an increased need to define the dynamics of cell trafficking and organ-specific accumulation. We examined how the presence of ARDS changes retention and organ-specific distribution of intravenously delivered MSCs isolated from subcutaneous adipose tissue [adipose-derived stem cells (ADSCs)]. This type of cell therapy was previously shown to ameliorate ARDS pathology. ARDS was triggered by lipopolysaccharide (LPS) aspiration, 4 h after which 300,000 murine CRE+ ADSCs were delivered intravenously. The distribution of ADSCs in the lungs and other organs was assessed by real-time polymerase chain reaction (PCR) of genomic DNA. As anticipated, the majority of delivered ADSCs accumulated in the lungs of both control and LPS-challenged mice, with minor amounts distributed to the liver, kidney, spleen, heart, and brain. Interestingly, within 2 h following ADSC administration, LPS-challenged lungs retained significantly lower levels of ADSCs compared to control lungs (~7% vs. 15% of the original dose, respectively), whereas the liver, kidney, spleen, and brain of ARDS-affected animals retained significantly higher numbers of ADSCs compared to control animals. In contrast, 48 h later, only LPS-challenged lungs continued to retain ADSCs (~3% of the original dose), whereas the lungs of control animals and nonpulmonary organs in either control or ARDS mice had no detectable levels of ADSCs. Our data suggest that the pulmonary microenvironment during ARDS may lessen the pulmonary capillary occlusion by MSCs immediately following cell delivery while facilitating pulmonary retention of the cells.

Original languageEnglish (US)
Pages (from-to)1635-1643
Number of pages9
JournalCell Transplantation
Volume25
Issue number9
DOIs
StatePublished - 2016

Fingerprint

Adult Respiratory Distress Syndrome
Stromal Cells
Stem cells
Stem Cells
Lung
Mesenchymal Stromal Cells
Lipopolysaccharides
Animals
Cell- and Tissue-Based Therapy
Liver
Organ Trafficking
Brain
Spleen
Animal Structures
Kidney
Subcutaneous Fat
Polymerase chain reaction
Lung Injury
Pathology
Real-Time Polymerase Chain Reaction

Keywords

  • Acute respiratory distress syndrome (ARDS)
  • Adipose-derived stem cells (ADSCs)
  • Retention
  • Transplantation

ASJC Scopus subject areas

  • Biomedical Engineering
  • Cell Biology
  • Transplantation

Cite this

Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS. / Lu, Hongyan; Cook, Todd; Poirier, Christophe; Merfeld-Clauss, Stephanie; Petrache, Irina; March, Keith L.; Bogatcheva, Natalia.

In: Cell Transplantation, Vol. 25, No. 9, 2016, p. 1635-1643.

Research output: Contribution to journalArticle

Lu, Hongyan ; Cook, Todd ; Poirier, Christophe ; Merfeld-Clauss, Stephanie ; Petrache, Irina ; March, Keith L. ; Bogatcheva, Natalia. / Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS. In: Cell Transplantation. 2016 ; Vol. 25, No. 9. pp. 1635-1643.
@article{e4188492b3514feb864056fedb02c69d,
title = "Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS",
abstract = "Transplantation of mesenchymal stromal cells (MSCs) has been shown to effectively prevent lung injury in several preclinical models of acute respiratory distress syndrome (ARDS). Since MSC therapy is tested in clinical trials for ARDS, there is an increased need to define the dynamics of cell trafficking and organ-specific accumulation. We examined how the presence of ARDS changes retention and organ-specific distribution of intravenously delivered MSCs isolated from subcutaneous adipose tissue [adipose-derived stem cells (ADSCs)]. This type of cell therapy was previously shown to ameliorate ARDS pathology. ARDS was triggered by lipopolysaccharide (LPS) aspiration, 4 h after which 300,000 murine CRE+ ADSCs were delivered intravenously. The distribution of ADSCs in the lungs and other organs was assessed by real-time polymerase chain reaction (PCR) of genomic DNA. As anticipated, the majority of delivered ADSCs accumulated in the lungs of both control and LPS-challenged mice, with minor amounts distributed to the liver, kidney, spleen, heart, and brain. Interestingly, within 2 h following ADSC administration, LPS-challenged lungs retained significantly lower levels of ADSCs compared to control lungs (~7{\%} vs. 15{\%} of the original dose, respectively), whereas the liver, kidney, spleen, and brain of ARDS-affected animals retained significantly higher numbers of ADSCs compared to control animals. In contrast, 48 h later, only LPS-challenged lungs continued to retain ADSCs (~3{\%} of the original dose), whereas the lungs of control animals and nonpulmonary organs in either control or ARDS mice had no detectable levels of ADSCs. Our data suggest that the pulmonary microenvironment during ARDS may lessen the pulmonary capillary occlusion by MSCs immediately following cell delivery while facilitating pulmonary retention of the cells.",
keywords = "Acute respiratory distress syndrome (ARDS), Adipose-derived stem cells (ADSCs), Retention, Transplantation",
author = "Hongyan Lu and Todd Cook and Christophe Poirier and Stephanie Merfeld-Clauss and Irina Petrache and March, {Keith L.} and Natalia Bogatcheva",
year = "2016",
doi = "10.3727/096368915X690189",
language = "English (US)",
volume = "25",
pages = "1635--1643",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "9",

}

TY - JOUR

T1 - Pulmonary retention of adipose stromal cells following intravenous delivery is markedly altered in the presence of ARDS

AU - Lu, Hongyan

AU - Cook, Todd

AU - Poirier, Christophe

AU - Merfeld-Clauss, Stephanie

AU - Petrache, Irina

AU - March, Keith L.

AU - Bogatcheva, Natalia

PY - 2016

Y1 - 2016

N2 - Transplantation of mesenchymal stromal cells (MSCs) has been shown to effectively prevent lung injury in several preclinical models of acute respiratory distress syndrome (ARDS). Since MSC therapy is tested in clinical trials for ARDS, there is an increased need to define the dynamics of cell trafficking and organ-specific accumulation. We examined how the presence of ARDS changes retention and organ-specific distribution of intravenously delivered MSCs isolated from subcutaneous adipose tissue [adipose-derived stem cells (ADSCs)]. This type of cell therapy was previously shown to ameliorate ARDS pathology. ARDS was triggered by lipopolysaccharide (LPS) aspiration, 4 h after which 300,000 murine CRE+ ADSCs were delivered intravenously. The distribution of ADSCs in the lungs and other organs was assessed by real-time polymerase chain reaction (PCR) of genomic DNA. As anticipated, the majority of delivered ADSCs accumulated in the lungs of both control and LPS-challenged mice, with minor amounts distributed to the liver, kidney, spleen, heart, and brain. Interestingly, within 2 h following ADSC administration, LPS-challenged lungs retained significantly lower levels of ADSCs compared to control lungs (~7% vs. 15% of the original dose, respectively), whereas the liver, kidney, spleen, and brain of ARDS-affected animals retained significantly higher numbers of ADSCs compared to control animals. In contrast, 48 h later, only LPS-challenged lungs continued to retain ADSCs (~3% of the original dose), whereas the lungs of control animals and nonpulmonary organs in either control or ARDS mice had no detectable levels of ADSCs. Our data suggest that the pulmonary microenvironment during ARDS may lessen the pulmonary capillary occlusion by MSCs immediately following cell delivery while facilitating pulmonary retention of the cells.

AB - Transplantation of mesenchymal stromal cells (MSCs) has been shown to effectively prevent lung injury in several preclinical models of acute respiratory distress syndrome (ARDS). Since MSC therapy is tested in clinical trials for ARDS, there is an increased need to define the dynamics of cell trafficking and organ-specific accumulation. We examined how the presence of ARDS changes retention and organ-specific distribution of intravenously delivered MSCs isolated from subcutaneous adipose tissue [adipose-derived stem cells (ADSCs)]. This type of cell therapy was previously shown to ameliorate ARDS pathology. ARDS was triggered by lipopolysaccharide (LPS) aspiration, 4 h after which 300,000 murine CRE+ ADSCs were delivered intravenously. The distribution of ADSCs in the lungs and other organs was assessed by real-time polymerase chain reaction (PCR) of genomic DNA. As anticipated, the majority of delivered ADSCs accumulated in the lungs of both control and LPS-challenged mice, with minor amounts distributed to the liver, kidney, spleen, heart, and brain. Interestingly, within 2 h following ADSC administration, LPS-challenged lungs retained significantly lower levels of ADSCs compared to control lungs (~7% vs. 15% of the original dose, respectively), whereas the liver, kidney, spleen, and brain of ARDS-affected animals retained significantly higher numbers of ADSCs compared to control animals. In contrast, 48 h later, only LPS-challenged lungs continued to retain ADSCs (~3% of the original dose), whereas the lungs of control animals and nonpulmonary organs in either control or ARDS mice had no detectable levels of ADSCs. Our data suggest that the pulmonary microenvironment during ARDS may lessen the pulmonary capillary occlusion by MSCs immediately following cell delivery while facilitating pulmonary retention of the cells.

KW - Acute respiratory distress syndrome (ARDS)

KW - Adipose-derived stem cells (ADSCs)

KW - Retention

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84984618930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984618930&partnerID=8YFLogxK

U2 - 10.3727/096368915X690189

DO - 10.3727/096368915X690189

M3 - Article

C2 - 26609693

AN - SCOPUS:84984618930

VL - 25

SP - 1635

EP - 1643

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 9

ER -